IndustryCompany release

GeneDx reports $123.1M Q3 revenue, lowers growth guidance but lifts margin outlook

🇺🇸 GeneDx Holdings Corp. (WGS) · Mon 09 Nov 2026

The US genomic testing company kept its full-year revenue range, cut volume and revenue growth expectations, and raised its adjusted gross margin target to about 71%.

GeneDx Holdings reported third-quarter 2026 revenue of $123.1 million in an update published on 9 November 2026. Exome and genome test volume reached 32,134, a 25% increase on the same period a year earlier. Adjusted net income for the quarter was $8.6 million.

The company left its full-year revenue guidance unchanged at $475–490 million. It did, however, lower its expectations for growth. Exome and genome volume is now expected to grow by at least 28% for the year, and revenue by at least 17%.

Profitability guidance moved the other way. GeneDx raised its adjusted gross margin outlook to about 71% and set full-year adjusted net income at about $12 million. For the fourth quarter, it guided revenue to $135 million.

The update gives no further detail in the material available, so the reasons for the revised growth figures are not covered here.

What it means for your team

  • Market-access teams tracking genomic diagnostics can note a 25% year-on-year rise in exome and genome volume at GeneDx in Q3 2026.
  • Full-year volume growth guidance is now at least 28% and revenue growth at least 17%, while the $475–490 million revenue range is unchanged.
  • The adjusted gross margin outlook of about 71% is the main figure raised in this update.

Company's press release (SEC filing): GeneDx Holdings Corp. ↗

Article written by VigiEye from the official source (GeneDx Holdings Corp.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →